Using rib cartilage to treat ankle joint lesions
Evaluation of the Effectiveness and Safety of Autologous Costal Osteochondral Transplantation in the Treatment of Talar Osteochondral Lesions: a Randomized Controlled Clinical Trial
This study is testing whether using rib cartilage to treat ankle joint damage can help people recover better and have fewer side effects than a different treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | The Third Affiliated Hospital of Southern Medical University Government |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05942430 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness and safety of using autologous costal osteochondral transplantation to treat Hepple Stage V talar osteochondral lesions. Participants will be randomly assigned to receive either the experimental treatment or a control treatment involving autologous osteoperiosteal transplantation. The study aims to determine if the rib cartilage method leads to better clinical outcomes and less donor site morbidity compared to the control. All participants will follow the same rehabilitation and follow-up protocols post-surgery.
Who should consider this trial
Good fit: Ideal candidates are individuals with symptomatic Hepple stage V talar osteochondral lesions who have not responded to conservative treatment.
Not a fit: Patients with lower limb deformities, joint diseases in the hip or knee, or other specified conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve recovery outcomes and reduce complications for patients with severe ankle cartilage damage.
How similar studies have performed: While similar approaches have been explored, this specific method of using rib cartilage for ankle lesions is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points; * Failed conservative treatment for at least 6 months; * Unilateral talar osteochondral lesions without corresponding lesions on the tibial side; * Willingness to participate in this clinical trial and signing an informed consent form. Exclusion Criteria: * Combined with lower limb deformity. * Combined with hip or knee joint diseases. * Combined with ipsilateral ankle arthritis with joint space narrowing . * Diagnosis of gouty arthritis of the ankle joint. * Combined with osteoporosis (T score \<-2.5). * Other conditions considered inappropriate for participation in this clinical trial by the researchers.
Where this trial is running
Guangzhou, Guangdong
- The Third Affiliated Hospital of Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Canjun Zeng, PhD — The Third Affiliated Hospital of Southern Medical University
- Study coordinator: Hao Guo, MD
- Email: 416363977@qq.com
- Phone: +8617612003968
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.